ImmunAbs Gets FDA Phase 2 IND OK for IM-101 in Myasthenia Gravis
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug...